Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 03 07 2019
revised: 15 08 2019
accepted: 30 08 2019
pubmed: 9 9 2019
medline: 19 6 2020
entrez: 9 9 2019
Statut: ppublish

Résumé

Tumor location as a prognostic factor for patients with liposarcoma (LPS) has been studied modestly with varying outcomes. The aim was to establish the impact of tumor location on recurrence and survival of LPS patients. A retrospective database of patients treated for LPS until December 2017 was used to assess 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and disease-specific survival (DSS) per tumor location using the Kaplan-Meier method and log-rank test. A multivariable Cox regression analysis was performed to adjust for other prognostic factors. In total, 518 patients were identified with a median follow-up of 68 months (interquartile range 31-138). Patients with retroperitoneal/intrathoracic WDLPS or DDLPS (p = 0.014), or testicular WDLPS (p = 0.026) developed a local recurrence more often than patients with other tumor locations. No differences between LPS subtypes and tumor location in the development of metastases (p = 0.600) was observed. Five-year LRFS differed significantly between tumor locations (p < 0.001) as well as 5y-DSS (p < 0.001), but 5y-DMFS did not (p = 0.241), with retroperitoneal/intrathoracic LPS having a worse prognosis. Patients with WDLPS in the extremity, trunk or testicular region did not die of disease, except for the rare occasion of dedifferentiation upon recurrence. After adjustment for other prognostic factors, tumor location was only of prognostic value for DSS (retroperitoneal/intrathoracic vs. extremity: HR 5.08, 95% CI 2.41-10.71, p < 0.001). For all tumor locations, DSS mimicked DMFS except for retroperitoneal/intrathoracic LPS, where DSS mimicked LRFS and where DSS was worse than DMFS. This implies that these patients die of local disease instead of metastatic disease.

Sections du résumé

BACKGROUND BACKGROUND
Tumor location as a prognostic factor for patients with liposarcoma (LPS) has been studied modestly with varying outcomes. The aim was to establish the impact of tumor location on recurrence and survival of LPS patients.
METHODS METHODS
A retrospective database of patients treated for LPS until December 2017 was used to assess 5-year local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and disease-specific survival (DSS) per tumor location using the Kaplan-Meier method and log-rank test. A multivariable Cox regression analysis was performed to adjust for other prognostic factors.
RESULTS RESULTS
In total, 518 patients were identified with a median follow-up of 68 months (interquartile range 31-138). Patients with retroperitoneal/intrathoracic WDLPS or DDLPS (p = 0.014), or testicular WDLPS (p = 0.026) developed a local recurrence more often than patients with other tumor locations. No differences between LPS subtypes and tumor location in the development of metastases (p = 0.600) was observed. Five-year LRFS differed significantly between tumor locations (p < 0.001) as well as 5y-DSS (p < 0.001), but 5y-DMFS did not (p = 0.241), with retroperitoneal/intrathoracic LPS having a worse prognosis. Patients with WDLPS in the extremity, trunk or testicular region did not die of disease, except for the rare occasion of dedifferentiation upon recurrence. After adjustment for other prognostic factors, tumor location was only of prognostic value for DSS (retroperitoneal/intrathoracic vs. extremity: HR 5.08, 95% CI 2.41-10.71, p < 0.001).
CONCLUSION CONCLUSIONS
For all tumor locations, DSS mimicked DMFS except for retroperitoneal/intrathoracic LPS, where DSS mimicked LRFS and where DSS was worse than DMFS. This implies that these patients die of local disease instead of metastatic disease.

Identifiants

pubmed: 31493984
pii: S0748-7983(19)30660-2
doi: 10.1016/j.ejso.2019.08.026
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2437-2442

Informations de copyright

Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Auteurs

M Vos (M)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: m.vos.2@erasmusmc.nl.

W C Boeve (WC)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: w.boeve@erasmusmc.nl.

T M van Ginhoven (TM)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: t.vanginhoven@erasmusmc.nl.

S Sleijfer (S)

Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: s.sleijfer@erasmusmc.nl.

C Verhoef (C)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: c.verhoef@erasmusmc.nl.

D J Grünhagen (DJ)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015, GD Rotterdam, the Netherlands. Electronic address: d.grunhagen@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH